New study monitors infection risks in advanced myeloma drug
NCT ID NCT07564128
First seen May 04, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This Italian registry will follow 50 adults with relapsed/refractory multiple myeloma who are receiving elranatamab as part of their standard care. The goal is to track how many infections occur during the first year of treatment. The study does not test a new drug but aims to gather real-world data on infection patterns to improve patient management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elranatamab
What this could lead to
If successful, this study could help doctors better manage infection risks in patients receiving elranatamab for multiple myeloma.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove elranatamab's effectiveness or safety. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.